Drugs / MK-7145
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01558674 | May → Dec 2014 | heart failure, impaired renal function disease | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 1 | NCT01832103 | Aug → Dec 2013 | impaired renal function disease | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 1 | NCT01370655 | Jun → Dec 2011 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-7145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01558674 ↗ |
| Modality | Small molecule | — CHEMBL3696475 ↗ |
| Route | Oral | “MK-7145 3 mg (three x 1-mg MK-7145 capsules administered orally)” NCT01370655 ↗ |